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To the Editor
PARP14 is one of 18 poly-ADP ribosyl polymerase (PARP) family members that contain a
catalytic domain conferring ADP-ribosyltransferase activity, and was initially identified as a
transcriptional cofactor for signal transducer and activator of transcription (STAT)6
activity.1 Cytokine-stimulated STAT6 DNA binding activates PARP14 catalytic activity,
resulting in changes in target gene chromatin.2 Because STAT6 plays an obligate role in the
development of allergic inflammation,1 and other PARPs including PARP1 may contribute
to allergic inflammation,3 we previously assessed the requirement for PARP14 in the
development of allergic inflammation. In a model of allergic airway inflammation, mice
deficient in PARP14 had diminished cellular infiltrates, increased lung function, and
decreased TH2 cytokine production compared with control mice.4 Similarly, treatment of
wild-type mice with PARP inhibitors during or after the development of disease resulted in
decreased airway inflammation, TH2 cell development, and increased lung function
compared with control mice.4 At least part of the mechanism of PARP14 function was
through direct effects of PARP14 on TH2 cytokine genes, and the TH2 transcription factor
Gata3.4 However, the requirement for PARP14 in STAT6-dependent gene expression in
nonlymphoid cells, and whether PARP14 expression is altered in human disease, has not
been assessed.
We initially tested whether there are changes in the expression of members of the macro-
PARP subfamily of PARP genes in children with eosinophilic esophagitis (EoE) compared
with control samples. We obtained esophageal biopsies from children with EoE (Indiana
University [IU] population; see at www.jacionline.org) and control samples from children
who had esophageal biopsies for diagnostic purposes but did not have eosinophilic
esophagitis. RNA was isolated from biopsies, and cDNA was assessed for gene expression
by using quantitative PCR. We observed a 5.95-fold average increase in PARP14
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expression, a 3.1-fold average increase in PARP1 expression, and a decrease in PARP15
expression in EoE biopsies compared with controls (Fig 1, A). In contrast, there was no
significant difference in the expression of PARP9 (Fig 1, A).
To confirm this finding, we examined PARP14 expression in a population from Cincinnati
Children’s Hospital Medical Center through the use of high-throughput RNA sequencing.5
Compared with the IU population, this population had more severe inflammation5.
Following analysis of the RNA-sequencing data, we observed similar (4.5-fold) increases in
PARP14 expression as seen in the IU population (Fig 1, B).
The chemokine CCL26 (Eotaxin-3) is a critical component of the pathology of EoE. CCL26
expression is dramatically increased in biopsies from patients with EoE, and single
nucleotide polymorphisms in the CCL26 gene are associated with increased disease
incidence.6,7 Moreover, STAT6 regulates CCL26 in esophageal cells.8 To determine
whether PARP14 expression correlated with CCL26 expression, we tested the association of
expression of these 2 genes in esophageal biopsies from patients with EoE and observed a
strong correlation coefficient (IU population: R = 0.81; P = .0002, Cincinnati Children’s
Hospital Medical Center population: R = 0.61, P = .03) (Fig 1, C). In contrast, there was no
significant correlation between PARP1 and CCL26 expression (R = 0.30, P = .27). There is
significant heterogeneity in the expression of PARP14 in the biopsy samples, with some
overlap in the control biopsy samples (Fig 1, A). This heterogeneity was lessened in samples
from patients with more severe inflammation (Fig 1, B). Thus, PARP14 expression is
increased and CCL26 and PARP14 gene expression is correlated in 2 populations
interrogated by 2 distinct methods.
Because our results suggested a relationship between PARP14 and CCL26, we tested the
ability of PARP14 to regulate CCL26 directly. The esophageal cell line TE-7 was
transfected with a CCL26 luciferase reporter vector and plasmids encoding STAT6 and/or
PARP14 before incubation for 24 hours in the presence or absence of the STAT6-activating
cytokines IL-4 and IL-13. Consistent with previous results, transfection of STAT6-
expressing plasmids increased CCL26 reporter activity (Fig 2, A). Moreover, transfection of
PARP14 alone increased basal and cytokine-induced reporter activity (Fig 2, A).
Importantly, cotransfection of STAT6 and PARP14 significantly increased CCL26 reporter
activity over cells transfected with STAT6 alone (Fig 2, A). The effects of PARP14
expression were entirely dependent on STAT6 binding because they were not observed
when the plasmid was cotransfected with a CCL26 reporter that had a mutation in the
STAT6 binding site (Fig 2, A). These results suggested that PARP14 might be a viable target
for modulating the expression of CCL26. To test this directly, TE-7 cells were incubated
with IL-4 or IL-13 in the presence or absence of the PARP activity inhibitor PJ34 before
expression of the endogenous CCL26 gene was assessed. We observed that IL-4 and IL-13
increased CCL26 mRNA and that incubation with the PARP inhibitor attenuated the
induction in response to either cytokine (Fig 2, B). Similar results were observed in the TE-1
esophageal cell line. Thus, PARP14, and PARP activity, contribute to the regulation of
CCL26 in esophageal cells. These results do not exclude the possibility that PARP14 is
expressed by, and functions in, additional cell types that contribute to EoE.
Although we are only beginning to understand the in vivo functions of PARP14, this report,
coupled with our previous work,4 suggests that PARP14 has a significant role in the
development of allergic inflammation. It likely works in multiple cell types, including in T
cells, where it results in increased TH2 and TH9 development,4,9 and in target organ
epithelial cells, enhancing the production of proallergic chemokines. Our results raise the
possibility that targeting PARP14, or even PARP activity in general, might be an effective
therapy for allergic diseases including EoE.
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METHODS
Gene expression
RNA was isolated from the esophageal biopsies (IU population), and gene expression was
assessed for the indicated genes by using quantitative PCR. The mRNA expression of
CCL26 was determined by using the ΔCt method. RNA isolated from the Cincinnati
Children’s Hospital Medical Center population was sequenced at the Cincinnati Children’s
Hospital Medical Center Gene Discovery and Genetic Variation Core as previously
described.5
TE-7 esophageal epithelial cells were incubated in the presence or absence of IL-4 (2.5 ng/
mL) or IL-13 (20 ng/mL), with or without the PARP inhibitor PJ34 (25 μM). CCL26 mRNA
expression was assessed by using quantitative PCR.
Luciferase assay
TE-7 esophageal epithelial cells were transfected with a CCL26 luciferase reporter or a
reporter carrying a mutation in the STAT6 binding site, and control, STAT6-, or PARP14-
expressing plasmids. Cells were incubated in the presence or absence of IL-4 (25 ng/mL) or
IL-13 (25 ng/mL) for 24 hours before luciferase activity was assessed.
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FIG 1.
Correlation of PARP14 and CCL26 expression. A, Gene expression was assessed for the
indicated genes from IU population biopsies. Results are presented as percent of BACTIN
control. B, PARP14 expression in CCHMC population biopsies was determined by using
RNA sequencing. C, The mRNA expression of CCL26 was graphed against PAPR14
expression (IU population). Significance was determined by using ANOVA. CCHMC,
Cincinnati Children’s Hospital Medical Center; NL, normal. ***P < 10−3. FPKM, fragments
per kilobase of transcript per million mapped reads.
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FIG 2.
PARP14 activates the CCL26 gene. A, CCL26 promoter reporter activity with cotransfection
of STAT6-and/or PARP14-expressing plasmids into TE-7 esophageal cells. *P < .05; **P
< .001, compared with control plasmid transfection; ‡P < .05 compared with STAT6
transfection. B, CCL26 expression in cytokine-stimulated TE-7 esophageal cells incubated
with the PARP inhibitor PJ34. Results are the average of at least 3 experiments. *P < .05,
**P < .001, and ***P < .005. P values determined by using the Student t test.
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